BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abreu S, Silva F, Mendes R, Mendes TF, Teixeira M, Santo VE, Boghaert ER, Félix A, Brito C. Patient-derived ovarian cancer explants: preserved viability and histopathological features in long-term agitation-based cultures. Sci Rep 2020;10:19462. [PMID: 33173111 DOI: 10.1038/s41598-020-76291-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 da Mata S, Franchi-Mendes T, Abreu S, Filipe B, Morgado S, Mesquita M, Albuquerque C, Fonseca R, Santo VE, Boghaert ER, Rosa I, Brito C. Patient-Derived Explants of Colorectal Cancer: Histopathological and Molecular Analysis of Long-Term Cultures. Cancers (Basel) 2021;13:4695. [PMID: 34572922 DOI: 10.3390/cancers13184695] [Reference Citation Analysis]
2 Yee C, Dickson K, Muntasir MN, Ma Y, Marsh DJ. Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine. Front Bioeng Biotechnol 2022;10:836984. [DOI: 10.3389/fbioe.2022.836984] [Reference Citation Analysis]
3 Du Y, Miao W, Jiang X, Cao J, Wang B, Wang Y, Yu J, Wang X, Liu H. The Epithelial to Mesenchymal Transition Related Gene Calumenin Is an Adverse Prognostic Factor of Bladder Cancer Correlated With Tumor Microenvironment Remodeling, Gene Mutation, and Ferroptosis. Front Oncol 2021;11:683951. [PMID: 34150647 DOI: 10.3389/fonc.2021.683951] [Reference Citation Analysis]
4 Clark J, Fotopoulou C, Cunnea P, Krell J. Novel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research. Front Oncol 2022;12:837233. [PMID: 35402223 DOI: 10.3389/fonc.2022.837233] [Reference Citation Analysis]
5 Batalha S, Ferreira S, Brito C. The Peripheral Immune Landscape of Breast Cancer: Clinical Findings and In Vitro Models for Biomarker Discovery. Cancers (Basel) 2021;13:1305. [PMID: 33804027 DOI: 10.3390/cancers13061305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Templeton AR, Jeffery PL, Thomas PB, Perera MPJ, Ng G, Calabrese AR, Nicholls C, Mackenzie NJ, Wood J, Bray LJ, Vela I, Thompson EW, Williams ED. Patient-Derived Explants as a Precision Medicine Patient-Proximal Testing Platform Informing Cancer Management. Front Oncol 2021;11:767697. [PMID: 34988013 DOI: 10.3389/fonc.2021.767697] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Cox MC, Mendes R, Silva F, Mendes TF, Zelaya-Lazo A, Halwachs K, Purkal JJ, Isidro IA, Félix A, Boghaert ER, Brito C. Application of LDH assay for therapeutic efficacy evaluation of ex vivo tumor models. Sci Rep 2021;11:18571. [PMID: 34535719 DOI: 10.1038/s41598-021-97894-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ciucci A, Buttarelli M, Fagotti A, Scambia G, Gallo D. Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application. Cell Mol Life Sci 2022;79:364. [PMID: 35705879 DOI: 10.1007/s00018-022-04395-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]